Clinical Trials Browser

Phase NA × pralsetinib × 90 days × Clear all

NCT07418879 2026-02-18

A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung